SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Subscribe To Our Newsletter & Stay Updated
